We studied a cohort containing 368 children at high risk of developing atopy and atopic disorders and 540 parents of those children to investigate whether the IL13 Arg130Gln and CÀ1112 T polymorphisms were associated with these outcomes. We also investigated whether haplotypes consisting of any two polymorphisms of IL13 Arg130Gln, IL13 CÀ1112 T and IL4 CÀ589 T were associated with these phenotypes. In 288 white children, the IL13 130Gln allele was associated with atopy (RR ¼ 1.9, P ¼ 0.047), and with atopic dermatitis (RR ¼ 2.5, P ¼ 0.014). The associations were confirmed using a family-based test of association (P ¼ 0.027 and 0.030, respectively) in all subjects. In white subjects there were associations of haplotypes consisting of IL13 Arg130Gln and IL4 CÀ589 T with atopic dermatitis (P ¼ 0.006) and with atopy (P ¼ 0.009). Our data suggest that the IL13 Arg130Gln polymorphism and haplotypes consisting of IL13 Arg130Gln and IL4 CÀ589 T were associated with the development of atopy and atopic dermatitis at 24 months of age.
Atopy is an immune disorder characterized by increased immunoglobulin E (IgE) production and skin-prick test responsiveness after exposure to allergens. Atopy can exist without clinical manifestations, but it also underlies diseases such as asthma, allergic rhinitis and atopic dermatitis. It has been well documented that atopy is caused by the interaction of genetic and environmental factors. Some authors believe that the genetic contribution is more important than environmental factors.
Genomewide searches have identified strong linkage of a region on chromosome 5q31-33 with atopy and atopic diseases in different populations, [1] [2] [3] although the results of linkage studies of total IgE with 5q31-33 have not always been consistent. 4, 5 This region is rich in candidate genes involved in the IgE-mediated inflammatory response, in particular the genes encoding interleukin-4 (IL4) and interleukin-13 (IL13). [6] [7] [8] A T allele in the CÀ589 T polymorphism in the IL4 promoter, 9 referred as IL4 CÀ590 T polymorphism in different reports, [10] [11] [12] was associated with increased luciferase reporter gene activity. 13 The T allele was also associated with increased total IgE, asthma or asthma severity in other studies. 9, 12, 13 However, these associations were not replicated by other investigators. 10, 11 Two independent groups have demonstrated that IL13 plays a critical role in animal models of asthma. 14, 15 Subsequently, several association studies have reported associations of three polymorphisms of IL13 with atopy and atopic phenotypes. [16] [17] [18] [19] [20] [21] One polymorphism is located in the promoter region, at position À1112 (CÀ1112 T) relative to the transcription start site, 16 which was referred to as position À1055 17, 22 or À1111 18 in previous reports. The second polymorphism is located in the coding region, that is a G-A transition at nucleotide +2044 that leads to the Arg130Gln amino-acid substitution, 16, 19 which was referred to as Arg110Gln in the reports of Heinzman et al 20 and Arima et al. 21 The third polymorphism is located at the +2525 position (G2525A), which is in the 3 0 untranslated region, 16 and is the same as the +4738 polymorphism in the report by Howard et al. 18 Significant linkage disequilibrium was observed between the G2525A and Arg130Gln polymorphisms in both reports. 16, 18 However, the results of these studies are inconsistent with regard to the associated phenotypes. In addition, association of phenotypes with haplotypes of IL4 and IL13 has only rarely been analyzed. 23 Furthermore, the previous studies were cross-sectional family and casecontrol studies and consequently the relative risks associated with the polymorphisms and their haplotypes have not been investigated in a prospective cohort.
Therefore, we performed a prospective study in a cohort of children at high risk for atopy and atopic diseases. In this cohort, we have previously shown that the IL4-589 T allele is a risk factor for the development of atopy, asthma and rhinitis by 12 months of age. 24 In the present report, we determined whether the CÀ1112 T and Arg130Gln polymorphisms in the IL13 gene were associated with the development of atopy and atopic diseases at 24 months of age. We also determined whether haplotypes consisting of any two polymorphisms among IL13 Arg130Gln, IL13 CÀ1112 T and IL4 CÀ589 T were associated with these outcomes.
High-risk children, defined as those with at least one first-degree relative with asthma or two first-degree relatives with other IgE-mediated allergic diseases, were recruited from two centers (Vancouver and Winnipeg) for a study designed to assess the effectiveness of a multifaceted intervention program in the primary prevention of asthma and other atopic disorders. 25 The intervention program includes avoidance of house dust mite and pet allergens and environmental tobacco smoke, encouragement of breastfeeding, and supplementation with a partially hydrolyzed formula. 25 Among 545 families enrolled initially, 64 families dropped out of the study for various reasons by the end of 24 months of follow-up. DNA samples were available for 368 children and 540 parents of these children. Of the 368 children, 288 were whites and 26 were of Asian ancestry, the rest were of other ancestry.
Two pediatric allergists performed assessment of the children at 24 months for atopy and atopic diseases such as asthma, rhinitis without colds and atopic dermatitis. The definitions of 'probable' asthma, rhinitis without colds, atopic dermatitis, and atopy have been described previously. 24 In detail, because of the difficulty of diagnosing asthma at 24 months, we used a conservative definition of 'probable' asthma. 'Probable' asthma was defined as at least two distinct episodes of cough, each lasting for 2 or more weeks; or at least two distinct episodes of wheeze, each lasting for one or more weeks; plus at least one of the following: nocturnal cough at least once a week in the absence of a cold, hyperpneainduced cough or exercise-induced cough or wheeze at any time, response to treatment with beta-agonist and/or anti-inflammatory drugs. The definition of rhinitis without colds ('noninfectious' rhinitis) was two or more episodes of runny nose and sneezing without apparent colds. Atopic dermatitis was defined as characteristic skin lesion (scaly, erythematous and itchy) in at least two typical areas, for example, face, postauricular area, scalp, extensor surface of arms and legs, and flexures of neck, elbows, etc according to the definition of Hanifin and Lobitz. 26 Atopy was defined by the presence of a positive skin-prick test reaction (3 mm or greater mean wheal diameter than the negative control) to one or more of the following inhalant allergens: cat, dog, house dust mites (extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae), cockroach, Cladosporium, Alternaria, and to the following ingestant allergens: cow's milk, egg, soy, wheat and peanut.
In our previous study, there were genotypic data for the IL4 CÀ589 T polymorphism on 376 children. 24 In this study, we genotyped 326 and 329 children for the IL13 Arg130Gln and CÀ1112 T polymorphisms, respectively. These are lower numbers than the previous study because eight children dropped out of this study after 12 months, and we did not genotype nonwhite, nonAsian children for whom parental DNA was unavailable. The rationale for the latter exclusion was that data from these children would not have been included in any of the analyses presented here. The allele frequency of IL13 À1112 T was not significantly different between white and Asian children (19.6 and 7.5%, respectively, P ¼ 0.058). However, the allele frequencies of IL13 130Gln and IL4 À589 T were significantly different between white and Asian groups (20.1 vs 34.2% and 17.7 vs 82.7%, respectively, P ¼ 0.039 and o0.0001, respectively); therefore, we limited our association study to white subjects, of which we had the largest number of subjects. All of the three polymorphisms studied were in Hardy-Weinberg equilibrium in the white population.
The prevalence of 'probable' asthma, rhinitis without colds, atopic dermatitis and atopy at 24 months was compared in white children for genotype groups of the IL13 Arg130Gln, CÀ1112 T and IL4 CÀ589 T polymorphisms (Table 1) .
Significant associations were found for the IL13 Arg130Gln polymorphism in a dominant model for the IL13 130Gln allele with atopy and with atopic dermatitis. The relative risks of IL13 Gln/Gln and Arg/Gln genotypes compared with the Arg/Arg genotype for atopic dermatitis and atopy were 2.5 (P ¼ 0.014) and 1.9 (P ¼ 0.047), respectively. Binary logistic regression was used to calculate P-values adjusted for the presence/ Data are shown as % (n). The IL13 Arg130Gln, CÀ1112T and IL4 CÀ1112T polymorphisms were defined by PCR-RFLP as described. 16, 24 The frequencies of atopy and atopic diseases within each genotypic group were compared by w 2 analyses or by Fisher's exact test when applicable. w 2 tests assuming both dominant and recessive models for the rare allele were performed. Relative risks (RR) and 95% confidence intervals (CI) were calculated as previously described. 27 absence of the intervention (a potential confounding factor) using the JMP Statistics software package (SAS Institute Inc.). The associations remained significant after correction for intervention group with P-values of 0.017 and 0.049, respectively, although the association with atopy became borderline. However, no significant difference was found for phenotypic prevalence in genotypic groups of the IL13 C-1112 T polymorphism in either dominant or recessive models for IL13 À1112 T. For the IL4 CÀ589 T polymorphism, we found that the relative risk of À589TT compared with other genotypes for rhinitis was 3.4 (P ¼ 0.010), which was similar to that we reported previously at 12 months of age. 24 The association remained significant after correction for intervention group with a P-value of 0.021. Unlike previous results at 12 months of age, we did not find any association of the IL4 À589TT genotype with 'probable asthma' at 24 months of age.
In previous studies, IL13 130Gln has been associated with total serum IgE level, atopy, asthma and atopic dermatitis. 16, 18, 19, 28 Our results were consistent with the previous studies that showed that IL13 130Gln was associated with atopic dermatitis 19 and with atopy. 28 A recent study showed that IL13 130Gln might act as a functional genetic factor in the context of asthma with a unique mechanism to upregulate local and systemic IL13 concentration in vivo. 21 However, we did not find an association of IL13 130Gln with asthma, as was reported in case-control populations from both Britain and Japan, 20 but not in a Chinese population. 28 The IL13 À1112TT genotype was associated with serum IgE in three populations, 16 allergic asthma in a Dutch population and altered regulation of IL13 production. 17 Howard et al. 18 found that the IL13 À1112T allele was associated with asthma, bronchial hyperresponsiveness and atopy in another Dutch population. However, in this study we found no association of the IL13 CÀ1112T polymorphism with atopy and atopic diseases.
We have extended our previous IL4 CÀ589T report 24 by using phenotypic data from 24 months of age. The association of IL4 À589T with rhinitis remained similar at 24 months of age. However, the association of IL4 À589T with 'probable' asthma disappeared at 24 months of age. We did not find an association of IL4 À589T with atopic dermatitis as previously reported. 29 Prospective studies such as this are generally less prone to type 1 error due to population stratification because of the uniform method of ascertainment that is employed. However, there still remains the possibility that unidentified population structure is responsible for the associations with IL13 130Gln and IL4 À589T. Therefore, we used a family-based test of association implemented in the FBAT software. 30 By genotyping 540 parents of the children in this study for the IL13 Arg130Gln, IL13 CÀ1112T and IL4 CÀ589T polymorphisms, we were able to study 269 trios (ie genotypic data on a child and both of his/her parents). We performed family-based tests of association for those genotypes with each of the phenotypes in families from all ethnic backgrounds. The tests using affected offspring only are equivalent to the 'traditional' TDT, which was proposed as a test for association in the presence of linkage. 31 We did not find a significant transmission distortion using this test. In the case of atopic dermatitis or atopy, the IL13 130Gln allele was transmitted to the affected child approximately twice as often as the 130Arg allele. However, because of the small number of families in these analyses these distortions were not significant (P ¼ 0.074 and 0.103, respectively). We also calculated the P-value for the TDT using both affected and unaffected offspring and their parents, which can increase the power of the test. 32 In this test, the IL13 130Gln allele was transmitted preferentially to children who had atopic dermatitis (14 transmissions vs six nontransmissions) and was transmitted less often to children without atopic dermatitis at the same time point (63 transmissions vs 85 nontransmissions) (P ¼ 0.027). Similarly, the IL13 130Gln allele was transmitted preferentially to children who had a positive skin test (16 transmissions vs eight nontransmissions) and was transmitted less often to children without atopic dermatitis at the same time point (62 transmissions vs 83 nontransmissions) (P ¼ 0.030).
The results of theoretical studies indicate that including genotyped, unaffected offspring in association tests can increase power, especially with more common diseases. 32, 33 In our study, the associations of IL13 130Gln with atopic dermatitis and atopy were confirmed by TDT using both unaffected and affected offspring, which were not significant by TDT using only affected offspring.
There are several reasons for discrepancies between association studies of polymorphisms and atopy and atopic diseases. Firstly, the study population is an important factor affecting the result of a genetic study. Some genetic associations may be ethnicity dependent. 34 As shown in this and other studies, the frequency of the IL4 À589T allele in Asians (83%) is much higher than in white populations (18%). This may explain why the association of IL4 À589T with atopic dermatitis found in Japanese individuals was not found in white individuals. 29, 35 Even in the same ethnic group, there are various degrees of linkage disequilibrium. Significant linkage disequilibrium was observed between two IL13 polymorphisms in this study, but the D' of 0.46 was less than that (0.65) in the report of Graves et al. 16 In this report, linkage disequilibrium was also observed for IL4 CÀ589T polymorphism with either of the IL13 polymorphisms. Although the D' values were only 0.37 for IL4 CÀ589T and IL13 Arg130Gln, and 0.23 for IL4 CÀ589T and IL13 CÀ1112T, they were statistically significant with Po0.0001. However, no significant linkage disequilibrium between these two IL13 polymorphisms was found in the report of Howard et al. 18 Secondly, the age of the study subjects is also very important. It is difficult to diagnosis asthma in children at 24 months, so we used a definition of 'probable asthma'. About two-thirds of wheezing in infants is transient and is not associated with increased risk of asthma later in life. 36 In addition, the prevalence of allergic sensitization changes with age. The peak age of allergic sensitization is between 15 and 25 years, 37, 38 so skin tests in young children may not reflect their atopic status later in life. In a previous study, the prevalence of atopic dermatitis was shown to increase markedly during the first 12 months, while 'asthma-like' disease started to increase mainly after 12 months of age. 39 In this study, we found that 13 children were diagnosed as having 'probable asthma' at 12 months but not at 24 months of age (although some of these children may have recurrence of symptoms at a later date). In contrast, 21 children developed 'probable asthma' after 12 months of age. Only six children were diagnosed as 'probable asthma' at both 12 and 24 months of age. This agedependent penetrance of 'probable asthma' may explain discrepant results from studies that utilized subjects of different ages. It may also explain why we found different results by using 24-month phenotypic data. This emphasizes the value of a prospective study design and long-term follow-up.
Thirdly, the power of the study design to detect significant association varies in different reports. In our study, the frequencies of genotypes containing at least one risk allele were greater than 30% for each of the three polymorphisms. This translates to a power of 80% to detect an RR of 2.2 or greater (a ¼ 0.05, for a two-sided test). In the study of Howard et al, 18 the odds ratio for IL13 À1112T genotypes in subjects with asthma was only 1.9. Therefore, our negative results for the IL13 CÀ1112T polymorphism may be due to lack of power.
We found significant linkage disequilibrium between IL4 À589T and IL13 130Gln. This raises the possibility that neither of these alleles is responsible for these associations but instead they are in linkage disequilibrium with a third, causal allele. Therefore, we performed haplotype analysis among the different phenotypic groups. Haplotype analysis of haplotypes consisting of any two polymorphisms among IL13 Arg130Gln, IL13 CÀ1112T and IL4 CÀ589T showed that haplotypes composed of two polymorphisms of the IL13 gene were not associated with any phenotypes at 24 months of age (data not shown). However, haplotypes composed of IL13 Arg130Gln and IL4 CÀ589T polymorphisms were associated with atopic dermatitis and atopy with P-values of 0.006 and 0.009, respectively (Table 2 ). Haplotypes consisting of the IL13 CÀ1112T and IL4 CÀ589T polymorphisms were associated with atopic dermatitis with a P-value of 0.011 (data not shown). All four phenotypic groups had a decreased percentage of the IL13 130Arg/IL4 À589C haplotype, which is consistent with the data that these two alleles were lower risk alleles in previous studies of atopy and atopic diseases. Either the IL13 130Gln/IL4 À589C haplotype or the IL13 130Arg/IL4 À589T haplotype was significantly increased in both the atopic dermatitis and atopy groups. The associations with single polymorphisms could not explain these data. One explanation might be that there is a protective allele on the IL13 130Arg/IL4 À589C haplotype that is not found in the other three haplotypes.
In this study, we have used four outcome variables and genotypic data from three polymorphisms and therefore there may be concern regarding the number of comparisons that were made. However, we chose not to adjust the P-values for multiple comparisons because all phenotypes and all genotypes were not independent, and IL13 and IL4 are known atopy-susceptibility genes. Since the prevalence of atopic phenotypes changes with age in children, it is important to know which stage is most predictive of adult atopy and atopic diseases. Several studies have shown that the presence of atopic dermatitis in infancy is an important risk factor in subsequent development of asthma. 42, 43 A recent study has shown that skin sensitivity to egg or cow's milk in the first year, but not wheezing before the age of 2 years, was predictive of adult asthma. 44 Therefore, it is important to follow up this cohort to assess the outcomes of atopy and atopic diseases.
In summary, our data suggest that IL13 130Gln and IL4 À589T alleles are risk factors for the development of atopic dermatitis and atopy at 24 months of age. The haplotypes composed of these two polymorphisms were associated with atopic dermatitis and atopy. Haplotype frequencies between groups were compared by CLUMP software. 41 Data are shown as n (%).
